LOGICBIO THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 16th, 2020 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this "Agreement") is entered as of the last date set forth on the signature page below (the '''Effective date") by and between LogicBio Therapeutics, Inc. (the "Company") and Seokho Bryan Yoon ("Executive").
AMENDMENT NO. 3 TO AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • March 16th, 2020 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS AMENDMENT NO. 3 TO THE AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT (the “Amendment No. 3”) is made as of January 29, 2020 (“Amendment No. 3 Effective Date”), by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“Stanford”), and LogicBio Therapeutics, Inc., a Delaware corporation (“LogicBio”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Amended and Restated Exclusive (Equity) Agreement, dated as of January 31, 2018, by and between Stanford and LogicBio, as amended by that certain Amendment No. 1 dated as of May 3, 2018, and amended again by that certain Amendment No. 2, dated June 3, 2019, to Amended and Restated Exclusive (Equity) Agreement (the “Original Agreement,” and as amended by this Amendment No. 3, the “Agreement”).
Amendment No. 1 to Patent & Technology License AgreementPatent & Technology License Agreement • March 16th, 2020 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 to Patent & Technology License Agreement (“Amendment One”) is made and entered into as of October 14, 2019 (the “Effective Date”) by and between LogicBio Therapeutics, Inc. a Delaware corporation, having a principal place of business at 99 Erie Street, Cambridge, MA 02139 (“LogicBio”) and The Board of Regents (“Board”) of The University of Texas System (“System”, an agency of the State of Texas whose address is 210 West 7th Street, Austin, Texas 78701, on behalf of The University of Texas Southwestern Medical Center (“UT Southwestern”), a component institution of System, whose address is 5323 Harry Hines Boulevard, Dallas, Texas 75390-9094.
AMENDMENT NO. 1 TO AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • March 16th, 2020 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS AMENDMENT NO. 1 TO THE AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT (the “Amendment”) is made as of May 3, 2018, by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“Stanford”), and LogicBio Therapeutics, Inc., a Delaware corporation (“LogicBio”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Amended and Restated Exclusive (Equity) Agreement, dated as of January 31, 2018, by and between Stanford and LogicBio (the “Original Agreement,” and as amended by this Amendment, the “Agreement”).
